Trying to Conceive on a GLP-1: Fertility, Washout Timing, and the Honest Evidence

A drug that can help you conceive — and that you cannot take while conceiving

There is a paradox at the center of GLP-1s and fertility, and it is worth naming plainly before anything else. The same medication that can restore an ovulation you have not seen in months is also a medication you are meant to stop before you try to get pregnant. Both halves are true at once. Understanding why is the difference between an unplanned scare and a planned, intentional path to a pregnancy.

The "Ozempic baby" stories were not a myth and not magic. They were biology doing what the trials predict: in women whose cycles had gone quiet under the weight of obesity or PCOS, losing weight and easing insulin resistance let ovulation return — sometimes before anyone updated their assumptions about contraception. If you have spent years believing you could not easily conceive, that is a destabilizing thing to have change silently.

The fertility upside is real, and it is mostly mechanical

The evidence for a fertility benefit is best read as a benefit of what the drug does — weight and insulin — rather than a direct fertility drug effect. A 2026 narrative review of reproductive outcomes concluded that GLP-1 receptor agonists may improve ovulatory function and menstrual regularity, particularly in women with obesity or polycystic ovary syndrome, potentially increasing the likelihood of conception¹. The most concrete trial evidence is narrow but pointed: in a pilot randomized study, obese women with PCOS who had responded poorly to a first IVF cycle achieved higher pregnancy rates after a course of liraglutide with metformin². A dedicated 2026 fertility review, reporting that same trial, puts the numbers at 69.2% on liraglutide plus metformin against 35.4% on metformin alone, and reaches the same careful conclusion overall — a plausible pro-fertility effect, driven largely by metabolic improvement, on a still-thin evidence base³.

If your infertility is tied to weight or PCOS, in other words, a GLP-1 may be part of the preparation for pregnancy. It is the runway, not the takeoff. Our deeper look at GLP-1s and PCOS walks through how much of this rides on the metabolic engine — including the fact that liraglutide, not the newer molecules, carries most of that evidence.

Why you have to stop

The reason for stopping is not squeamishness; it is that human pregnancy-safety data are genuinely limited, and the shape of that limitation was measured this year. An international expert group ran a systematic scoping review of incretin-based medications across preconception, pregnancy and postnatal health, and found 34 articles in total: 11 randomized trials, nine observational studies, two pharmacovigilance reviews, nine case reports or series, two animal studies and one ex vivo study. They were able to find evidence for 18 of their 32 research questions. Two studies addressed contraception. One addressed lactation. Only one study — an animal one — had any data on offspring beyond birth. No study reported an increase in congenital anomalies⁴.

A 2026 case series shows what much of that literature looks like up close: sixteen patients at a tertiary perinatal center, all of whom conceived spontaneously and unplanned while using subcutaneous semaglutide and continued it into part of the first trimester. No major fetal anomalies were identified. The preeclampsia rate was 18.8%, and after stopping semaglutide most patients needed both metformin and insulin for glucose control⁵. Sixteen women is not a safety dataset. It is a set of individual outcomes, which is exactly the point: when the answer is "we don't have enough data," the responsible default in a planned pregnancy is not to expose the pregnancy at all.

The washout arithmetic — and it is not the same for both drugs

This is the single most important operational section on the page, and the two molecules genuinely differ.

Semaglutide. The Wegovy label instructs clinicians to discontinue the drug at least 2 months before a planned pregnancy, and says why in the same sentence: to account for the long half-life of semaglutide⁶. That is a two-month-ahead decision, which means you plan the stop on the same calendar where you plan the try.

Tirzepatide. The Zepbound label carries no pre-pregnancy washout instruction at all. What it says is to discontinue the drug when pregnancy is recognized⁷. That is a different rule, not a shorter version of the same one, and it is worth confirming with your own prescriber rather than assuming the semaglutide calendar transfers.

Two cautions on top of that. First, if you have seen "roughly a week per dose" quoted anywhere as the washout, that figure is describing the half-life, not the instruction, and it understates the semaglutide label's window by a very wide margin. Second, clinical reviews sometimes go further than the labels do: the 2026 fertility review recommends an 8-to-10-week washout before conception for semaglutide and tirzepatide³ — advice that exceeds what the tirzepatide label requires. That is not a contradiction to resolve on the internet. It is a reason to get a written stop date from the clinician who knows your history, at the conversation you have with your OB first.

The contraception catch that traps people going the other way

The mirror-image risk is for women who are not trying to conceive. Because a GLP-1 can quietly restore ovulation, contraception matters more on the drug than it may have before it — not less. And with tirzepatide (Zepbound, Mounjaro) there is a second, distinct problem: its label warns that oral hormonal contraceptives may be less effective because of delayed gastric emptying, and advises switching to a non-oral method or adding a barrier method for four weeks after initiation and four weeks after each dose escalation, while noting that non-oral hormonal methods should not be affected⁷. So the very medication that can reopen fertility can, if you take the tirzepatide family, also blunt the pill you were relying on. That is a two-sided trap, and it is exactly why we devote a whole piece to GLP-1s and birth control.

What women in this situation say is missing

There is one more evidence gap in the scoping review worth pulling out on its own, because it is unusual to see stated so flatly: across the entire literature that group searched, no qualitative studies were identified⁴. Thousands of women are navigating this exact decision and nobody has formally asked them what it is like.

The nearest thing is adjacent and it is instructive. A 2026 mixed-methods study at Hospital Clínic in Barcelona mapped the care journey of women living with both obesity and reproductive pathology, combining ten health-care professionals, a patient focus group, a co-creation workshop and a survey of 33 women who had been through that care. Some of the preconception care was rated positively. But the four things participants identified as needing to improve were personalized information, stigma-free emotional support, efficient use of their time, and shared decision-making⁸.

Read that list against everything above. A woman being handed a molecule with a two-month stop date, a contraception caveat that depends on which molecule she got, and a literature with sixteen-patient case series in it needs precisely those four things — information built for her, delivered without judgment, in time to act on, by someone treating the decision as hers. The gap between that list and a telehealth refill is the whole problem.

It is also worth checking whether the program asks the question at all, because several do not. PCOS Sisters is the sharpest example on our board: a practice built around PCOS, whose testimonials are largely about women getting pregnant, publishing no eligibility rule about pregnancy, conception or breastfeeding anywhere on its site. The only contraindication it lists is a family history of thyroid cancer. That is not a reason to rule it out. It is a reason to know, before you start, that this conversation will be yours to open.

Building the actual timeline

Put the pieces together and a real trying-to-conceive plan looks like this — and every date belongs to you and your clinician, not to a rule of thumb:

1. 1.While on the drug: treat restored ovulation as real. If you are not ready to conceive, use reliable contraception, and a non-oral or barrier method if you are on tirzepatide⁷.
2. 2.When you decide to try: plan the stop first, and get the date in writing — two months ahead under the semaglutide label⁶, and whatever your prescriber specifies on tirzepatide⁷. Folate and a general preconception check usually belong here too.
3. 3.After stopping: expect appetite and some weight to return as the medication leaves — that is the drug wearing off, not a personal failure. Our guide to coming off a GLP-1 and the rebound question covers that stretch honestly.
4. 4.After the baby: if you plan to breastfeed, the drug stays off the table; restarting is a later, separate conversation, and one of the least-studied questions in the whole field.

The honest bottom line

A GLP-1 can be part of getting ready to conceive — especially if weight or PCOS is in the picture — and must be out of your system before you actually do, on a schedule that depends on which drug you were given. The women who navigate this well plan the stop as deliberately as the start, with a clinician who can time the washout, manage the contraception, and switch molecules if needed.